CD274 and non-small cell lung carcinoma: In this single-arm phase II study, the efficacy and safety of atezolizumab and bevacizumab combination therapy in NS-NSCLC patients with PD-L1 TPS ≥50% were investigated to determine whether phase III studies are warranted.